Is methanol optic neuropathy treatable?

Session Details

Session Title: Free Paper Session 18: New Drug & Treatment Technology

Session Date/Time: Saturday 09/09/2017 | 14:30-16:00

Paper Time: 15:06

Venue: Room 120

First Author: : U.Kayabasi TURKEY

Co Author(s): :    V. Kaya                             

Abstract Details

Purpose:

Until recently, methanol optic neuropathy (MON) has been considered untreatable. There have been some trials focusing on this condition and some case studies were published. Our aim was to suggest a reliable treatment for this devastating problem.

Setting:

Liv Hospital- Istinye University/ Istanbul

Methods:

20 patients were examined after consuming illegal (fake) alcohol during the new year eve’s holiday period in the southern parts of Turkey. All the patients were male and the mean age was 58. Intravenous erythropoietin (8000 iu/bid) and methylprednisolone (1 gr/bid) were given simultaneously for 3 days in 10 patients. The second group received the same therapy, but methylprednisolone was administered half an hour after the erythropoietin treatment. Pentoxyfilline oral tablets and intramuscular combined B group vitamins were also used in both groups.

Results:

Patients who received the simultaneous therapy recovered better and more quickly than the other group. VA, after 2 months, was better more than 2 lines (by Snellen Chart) in the first group plus visual fields improved statistically significantly more than the ones in the second group considering Mean Deviation changes. (P: 0,005) 2 patients in the first group enjoyed full vision with no defects on OCT retinal fiber layer examination.

Conclusions:

We believe that MON can be treated and simultaneous administration of both intravenous medications seems to show a synergistic effect.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy